Peptide therapy is not one-size-fits-all
The reported 12-hour growth hormone exposure was around 260 mUmin/L with GHRP-6 alone and about 159 mUmin/L with the GHRH analogue alone, but increased to roughly 729 mUmin/L when the two were combined
How BPC-157 might help to achieve such results, however, is a bit uncertain
The newly identified features of the disease increasingly regard PAH as a multipronged disease involving multiple points of interaction between genetics, metabolomics, imbalance of vasoconstrictor and vasodilator responses, endothelial and smooth muscle dysfunction, thrombosis and platelet dysregulation, and mitochondrial and miRNA abnormalities
The injectable form bypasses this enzymatic degradation and delivers the active tripeptide directly into the circulation (Richie et al., Eur J Nutr 2015)